Nektar Therapeutics has pivoted from oncology to focus on autoimmune and inflammatory diseases. Read why I rate NKTR stock a ...
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...
Medpage Today on MSN
Regulatory T-Cell Drug Promising for Eczema, With Hint for Asthma as Well
For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...
Now, it’s worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 194% for ...
The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...
With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...
Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD ...
Apogee is gearing up for a potentially transformative 2026 from a position of strength. With four key readouts coming in 2026 and the recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback